NASDAQ:CMRX

Chimerix - CMRX Stock Forecast, Price & News

$1.80

+0.02 (+1.12%)

(As of 01/27/2023 12:00 AM ET)

Add

Compare

Today's Range: $1.76
▼
$1.83
50-Day Range: $1.70
▼
$2.35
52-Week Range: $1.27
▼
$6.43

Volume: 400,595 shs
Average Volume: 614,277 shs
Market Capitalization: $158.48 million

P/E Ratio: 1.03
Dividend Yield: N/A
Price Target: $8.50

Institutional Ownership

Chimerix MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 372.2% Upside
$8.50 Price Target
Short Interest: Healthy
3.57% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.49
Upright™ Environmental Score
News Sentiment: 0.51
Based on 3 Articles This Week
Insider Trading: Selling Shares
$5,685 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From $1.97 to ($0.90) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

199th out of 1,055 stocks

Pharmaceutical Preparations Industry

91st out of 519 stocks

3.5

Analyst's Opinion

Consensus Rating
Chimerix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.50, Chimerix has a forecasted upside of 372.2% from its current price of $1.80.
Amount of Analyst Coverage
Chimerix has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.57% of the float of Chimerix has been sold short.
Short Interest Ratio / Days to Cover
Chimerix has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Chimerix has recently increased by 4.33%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Chimerix does not currently pay a dividend.
Dividend Growth
Chimerix does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Chimerix has received a 58.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Pox medications" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for Chimerix is -2.49.

2.0

News and Social Media Coverage

News Sentiment
Chimerix has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Chimerix this week, compared to 3 articles on an average week.
Search Interest
Only 5 people have searched for CMRX on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.
MarketBeat Follows
6 people have added Chimerix to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Chimerix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,685.00 in company stock.
Percentage Held by Insiders
Only 8.20% of the stock of Chimerix is held by insiders.
Percentage Held by Institutions
58.03% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Chimerix are expected to decrease in the coming year, from $1.97 to ($0.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Chimerix is 1.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.57.
Price to Earnings Ratio vs. Sector
The P/E ratio of Chimerix is 1.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 144.46.
Price to Book Value per Share Ratio
Chimerix has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Chimerix (NASDAQ:CMRX) Stock

Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

CMRX Stock News Headlines

January 5, 2023 | finance.yahoo.com

Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023 | thestreet.com

Why Chimerix (CMRX) Stock Is Tanking Today

January 27, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

November 29, 2022 | finance.yahoo.com

Chimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?

November 14, 2022 | bizjournals.com

Hedge fund urges Durham drugmaker Chimerix to liquidate

November 10, 2022 | finance.yahoo.com

Rubric Capital Management Sends Letter to Chimerix Board of Directors

November 10, 2022 | finance.yahoo.com

Chimerix Responds to Rubric Capital Management

November 4, 2022 | finance.yahoo.com

Buy 3 of the Best Stocks by Using Net Income Ratio

January 27, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

November 3, 2022 | finance.yahoo.com

Chimerix (CMRX) Beats Q3 Earnings Estimates

November 3, 2022 | finance.yahoo.com

Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update

October 27, 2022 | finance.yahoo.com

Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022

October 11, 2022 | nasdaq.com

Will UnitedHealth Group (UNH) Beat Q3 Earnings Estimates? - Nasdaq

October 5, 2022 | proactiveinvestors.com

Kazia Therapeutics takes Phase 2 study of paxalisib international; opens two sites in Australia - Proactive Investors USA

October 5, 2022 | uk.investing.com

$1.2 Million Bet On ChromaDex? Check Out These 4 Penny Stocks Insiders Are Buying By Benzinga - Investing.com UK

September 28, 2022 | bizjournals.com

Durham pharma nets $238M for smallpox drug with more payouts lined up - The Business Journals

September 27, 2022 | finance.yahoo.com

Emergent BioSolutions closes acquisition of smallpox drug from Chimerix

September 26, 2022 | globenewswire.com

Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages - GlobeNewswire

September 26, 2022 | globenewswire.com

Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions - GlobeNewswire

September 11, 2022 | nasdaq.com

We Think Chimerix (NASDAQ:CMRX) Needs To Drive Business Growth Carefully - Nasdaq

September 10, 2022 | finance.yahoo.com

Institutional investors own a significant stake of 49% in Chimerix, Inc. (NASDAQ:CMRX)

September 6, 2022 | benzinga.com

Chimerix (CMRX) – Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference - Benzinga

September 6, 2022 | finance.yahoo.com

Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 2, 2022 | nasdaq.com

Implied Volatility Surging for Chimerix (CMRX) Stock Options - Nasdaq

September 1, 2022 | finance.yahoo.com

Implied Volatility Surging for Chimerix (CMRX) Stock Options

August 31, 2022 | benzinga.com

(BVNRY), Chimerix (CMRX) – Testing, Treatment, and Vaccines are the Three Ways Companies Can Fight Monkey - Benzinga

August 31, 2022 | benzinga.com

Chimerex, Inc. (CMRX) – Chimerix's Return On Capital Employed Insights - Benzinga

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

CMRX Company Calendar

Last Earnings: 11/03/2022
Today: 1/27/2023
Next Earnings (Estimated): 3/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CMRX
CUSIP: N/A
CIK: 1117480
Web: www.chimerix.com
Phone: (919) 806-1074
Fax: 919-806-1146
Employees: 87
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.50
High Stock Price Forecast: $11.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +372.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.75
Trailing P/E Ratio: 1.03
Forward P/E Ratio: 0.91
P/E Growth: N/A
Net Income: $-173,240,000.00
Net Margins: 464.75%
Pretax Margin: 465.22%
Return on Equity: 147.04%
Return on Assets: 119.67%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.44
Quick Ratio: 16.44

Sales & Book Value

Annual Sales: $1.98 million
Price / Sales: 80.04
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.79 per share
Price / Book: 2.28

Miscellaneous

Outstanding Shares: 88,045,000
Free Float: 80,825,000
Market Cap: $158.48 million
Optionable: Optionable
Beta: 1.17

Key Executives

Mr. Michael A. Sherman M.B.A. (Age 57)
CEO, Pres & Director
Comp: $987.2k

Mr. Michael T. Andriole M.B.A. (Age 50)
Chief Bus. Officer, Sec. & CFO
Comp: $616.9k

Dr. Allen S. Melemed M.B.A. (Age 59)
M.D., Chief Medical Officer
Comp: $622.17k

Mr. David Jakeman CPA (Age 45)
Exec. Director of Fin. & Accounting and Principal Accounting Officer

Dr. Roy W. Ware
Chief Manufacturing & Technology Officer

Dr. Randall Lanier
Chief Science Officer

Ms. Michelle LaSpaluto
VP of Strategic Planning & Investor Relations

Dr. Michael A. Alrutz (Age 53)
Sr. VP, Gen. Counsel & Corp. Sec.

Dr. Joshua E. Allen
Chief Technology Officer of Imipridones

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CMRX Stock - Frequently Asked Questions

Should I buy or sell Chimerix stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CMRX shares.
View CMRX analyst ratings or view top-rated stocks.
What is Chimerix's stock price forecast for 2023?: 3 equities research analysts have issued 12 month price objectives for Chimerix's stock. Their CMRX share price forecasts range from $6.00 to $11.00. On average, they anticipate the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 368.3% from the stock's current price.
View analysts price targets for CMRX or view top-rated stocks among Wall Street analysts.
How have CMRX shares performed in 2023?: Chimerix's stock was trading at $1.86 at the start of the year. Since then, CMRX stock has decreased by 2.4% and is now trading at $1.8150.
View the best growth stocks for 2023 here.
When is Chimerix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our CMRX earnings forecast.
How were Chimerix's earnings last quarter?: Chimerix, Inc. (NASDAQ:CMRX) released its quarterly earnings data on Thursday, November, 3rd. The biopharmaceutical company reported $2.75 EPS for the quarter, beating analysts' consensus estimates of $2.10 by $0.65. The biopharmaceutical company had revenue of $32.56 million for the quarter, compared to analyst estimates of $205.30 million. Chimerix had a net margin of 464.75% and a trailing twelve-month return on equity of 147.04%.

What other stocks do shareholders of Chimerix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), VBI Vaccines (VBIV) and TherapeuticsMD (TXMD).
What is Chimerix's stock symbol?: Chimerix trades on the NASDAQ under the ticker symbol "CMRX."
Who are Chimerix's major shareholders?: Chimerix's stock is owned by many different retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.43%), Assenagon Asset Management S.A. (0.30%), Strs Ohio (0.09%) and Clear Harbor Asset Management LLC (0.03%). Insiders that own company stock include David Jakeman, Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer.
View institutional ownership trends.
How do I buy shares of Chimerix?: Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Chimerix's stock price today?: One share of CMRX stock can currently be purchased for approximately $1.82.
How much money does Chimerix make?: Chimerix (NASDAQ:CMRX) has a market capitalization of $159.80 million and generates $1.98 million in revenue each year. The biopharmaceutical company earns $-173,240,000.00 in net income (profit) each year or $1.75 on an earnings per share basis.
How can I contact Chimerix?: Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The official website for the company is www.chimerix.com. The biopharmaceutical company can be reached via phone at (919) 806-1074, via email at ir@chimerix.com, or via fax at 919-806-1146.

This page (NASDAQ:CMRX) was last updated on 1/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Chimerix - CMRX Stock Forecast, Price & News

Chimerix MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Chimerix (NASDAQ:CMRX) Stock

CMRX Stock News Headlines

CMRX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CMRX Stock - Frequently Asked Questions

Overall MarketRank^™